| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0092-8674(84)90532-4 |
| P698 | PubMed publication ID | 6088057 |
| P50 | author | Varda Rotter | Q16131089 |
| P2093 | author name string | Wolf D | |
| Harris N | |||
| P2860 | cites work | Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species | Q36942353 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell line | Q21014462 |
| P304 | page(s) | 119-126 | |
| P577 | publication date | 1984-08-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. | |
| P478 | volume | 38 |
| Q33612442 | A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells |
| Q37599465 | A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs |
| Q72293593 | A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice |
| Q33880321 | Abelson transformed fibroblasts lacking the EGF receptor are not tumourigenic in nude mice |
| Q39575066 | Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain |
| Q39672951 | Activation of cellular oncogenes in human and mouse leukemia-lymphomas: spontaneous and induced oncogene expression in murine B lymphocytic neoplasms |
| Q38934098 | Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? |
| Q56341291 | Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer |
| Q36065506 | An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control |
| Q51033341 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. |
| Q41243025 | Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells. |
| Q77292526 | Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers |
| Q40669877 | Characterization of the human p53 gene |
| Q35103336 | Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. |
| Q74610152 | Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma |
| Q36835468 | Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation |
| Q71820075 | Dominant‐negative p53 can restore tumorigenicity of L‐929 cells in immunocompetent mice |
| Q40791236 | Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. |
| Q36647653 | Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells |
| Q68223052 | Expression of proto-oncogenes in xenografts of human renal cell carcinomas |
| Q36352855 | Expression of the p53 oncogene in acute myeloblastic leukemia |
| Q41844172 | Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines |
| Q35101216 | Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 |
| Q36760672 | High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene |
| Q35673678 | High metastatic potential in mice inheriting a targeted p53 missense mutation |
| Q91701456 | How TP53 (almost) became an oncogene |
| Q33632309 | Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. |
| Q36867104 | Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex |
| Q36896541 | Immunologically distinct p53 molecules generated by alternative splicing |
| Q40666508 | In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene |
| Q36714239 | Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles |
| Q34462553 | Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. |
| Q36874318 | Integration of Friend murine leukemia virus into both alleles of the p53 oncogene in an erythroleukemic cell line |
| Q28345092 | Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis |
| Q33292223 | Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins |
| Q37604186 | Involvement of wild-type p53 in pre-B-cell differentiation in vitro |
| Q40665592 | Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule |
| Q40046858 | Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformation |
| Q39041480 | Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition |
| Q34179671 | Localization of gene for human p53 tumour antigen to band 17p13. |
| Q37676784 | Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells |
| Q40421511 | Mammalian p53 can function as a transcription factor in yeast |
| Q40667913 | Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function |
| Q30374671 | Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. |
| Q40062749 | Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. |
| Q36902414 | Molecular basis for heterogeneity of the human p53 protein |
| Q36105857 | Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. |
| Q40127251 | Monoclonal antibody analysis of p53 expression in normal and transformed cells |
| Q36918577 | Multistage Friend erythroleukemia: independent origin of tumor clones with normal or rearranged p53 cellular oncogenes. |
| Q58736829 | Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma |
| Q24681272 | Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II |
| Q36698822 | Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity |
| Q49791721 | Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. |
| Q77932308 | Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q40265316 | Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. |
| Q36958607 | Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest |
| Q33737277 | Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators |
| Q36070574 | Mutant p53: one name, many proteins |
| Q39882046 | Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. |
| Q37629482 | Mutation of the endogenous p53 gene in cells transformed by HPV-16 E7 and EJ c-ras confers a growth advantage involving an autocrine mechanism |
| Q36803951 | Mutation of the serine 312 phosphorylation site does not alter the ability of mouse p53 to inhibit simian virus 40 DNA replication in vivo |
| Q28208559 | Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil |
| Q40647696 | Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q64517981 | Oncogenic intelligence: Cell immortalization and transformation by the p53 gene |
| Q38045766 | Overexpression of p53 protein in human tumors |
| Q36897747 | Overproduction of protein p53 contributes to simian virus 40-mediated transformation |
| Q36781515 | Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells |
| Q39653370 | RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells |
| Q74355214 | RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome |
| Q34360802 | Rearrangement of the p53 gene in human osteogenic sarcomas |
| Q45828140 | Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus |
| Q35099531 | Recent advances in p53 research and cancer treatment |
| Q24655012 | Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene |
| Q40011883 | Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants |
| Q28273002 | Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 |
| Q37043126 | Retroviral Mutagenesis of Cellular Oncogenes: A Review with Insights into the Mechanisms of Insertional Activation |
| Q39704190 | Role of the ABL oncogene tyrosine kinase activity in human leukaemia |
| Q39159055 | Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells |
| Q41459547 | Significance of P53 in human thyroid tumors |
| Q36591517 | Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells |
| Q36758893 | Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment |
| Q40040456 | Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences |
| Q43718785 | The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis |
| Q26772237 | The Contrived Mutant p53 Oncogene - Beyond Loss of Functions |
| Q40976806 | The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53. |
| Q34402080 | The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth |
| Q24645732 | The first 30 years of p53: growing ever more complex |
| Q41194136 | The genotype of the human cancer cell: implications for risk analysis. |
| Q40404822 | The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene |
| Q40867777 | The molecular and genetic characterization of human soft tissue tumors. |
| Q37751892 | The p53 tumour suppressor gene |
| Q38198487 | The paradigm of mutant p53-expressing cancer stem cells and drug resistance |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q40851672 | The role of hepatitis B virus in development of primary hepatocellular carcinoma: Part II. |
| Q41486644 | The role of p53 in growth of mouse fibroblast lines |
| Q37537138 | The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines |
| Q34045809 | The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. |
| Q39320781 | The viral and cellular forms of the Abelson (abl) oncogene |
| Q47742599 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others |
| Q34055161 | Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. |
| Q36671026 | Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. |
| Q36777349 | Transcription regulation by mutant p53. |
| Q29617436 | Tumor spectrum analysis in p53-mutant mice |
| Q41625163 | Tumor suppressor genes and human cancer |
| Q27000754 | Tumor suppressor p53 and its gain-of-function mutants in cancer |
| Q34314048 | Tumor suppressor p53 mutations and breast cancer: a critical analysis |
| Q36908146 | Tumorigenicity of fibroblast lines expressing the adenovirus E1a, cellular p53, or normal c-myc genes |
| Q64236647 | Understanding p53 functions through p53 antibodies |
| Q35609631 | Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients |
| Q41708689 | Viral and cellular oncogene expression during progressive malignant transformation of SV40 transformed human fibroblasts |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q30450825 | Wild-type p53 can inhibit oncogene-mediated focus formation |
| Q36895398 | p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors |
| Q40649790 | p53 increases experimental metastatic capacity of murine carcinoma cells |
| Q33750337 | p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer |
| Q41640484 | p53 tumor-suppressor gene: clues to molecular carcinogenesis |
| Q83365205 | p53: more research and more questions |
Search more.